natgillin/translations-raw huggingface dataset:
The analysis of all recorded incremental recoveries in previously treated patients demonstrated a median rise of > 2% (> 2 IU/dL) per IU/kg body weight for Kovaltry.
Analiza vseh zabeleženih postopnih izboljšanj pri predhodno zdravljenih bolnikih je pokazala mediano povečanja za > 2 % (> 2 i.e./dl) na i.e./kg telesne mase za zdravilo Kovaltry.
The analysis of immunogenicity was conducted on ATP cohort for immunogenicity. tested at GSK laboratories
Analizo imunogenosti so opravili na kohorti ATP za imunogenost. testirano v laboratorijih družbe GSK
The analysis of immunogenicity was conducted on ATP cohort for immunogenicity. tested at GSK laboratories Children
Analizo imunogenosti so opravili na kohorti ATP za imunogenost.
The analysis of immunogenicity was conducted on ATP cohort for persistence adapted for each time- point.
Analizo imunogenosti so opravili na kohorti ATP za trajanje, prilagojeno za vsako časovno točko.
The analysis of immunogenicity was conducted on ATP cohort for persistence adapted for each time- point. tested at GSK laboratories
Analizo imunogenosti so opravili na kohorti ATP za trajanje, prilagojeno za vsako časovno točko. testirano v laboratorijih družbe GSK
The analysis of immunogenicity was conducted on ATP cohort for persistence. tested at GSK laboratories Adolescents and Adults
Analizo imunogenosti so opravili na kohorti ATP za trajanje. testirano v laboratorijih družbe GSK Mladostniki in odrasli
The analysis of immunogenicity was conducted on ATP cohorts for immunogenicity.
Analizo imunogenosti so opravili na kohorti ATP za imunogenost.
The analysis of immunogenicity was conducted on the according-to-protocol (ATP) cohort for immunogenicity
Analizo imunogenosti so opravili na kohorti ATP za imunogenost.
The analysis of immunogenicity was conducted on the ATP cohorts for immunogenicity.
Analizo imunogenosti so opravili na kohortah ATP (ATP – According-to-Protocol) za imunogenost.
The analysis of overall survival showed a significant benefit of R-FC treatment over FC chemotherapy alone (p = 0.0319, log-rank test) (Table 2a).
Analiza celokupnega preživetja je pokazala signifikantno korist zdravljenja R-FC glede na samo kemoterapijo FC (p = 0,0319, test log rank) (preglednica 2a).
The analysis of overall survival showed a significant benefit of R-FC treatment over FC chemotherapy alone (p = 0.0319, log-rank test) (Table 8a).
Analiza celokupnega preživetja je pokazala signifikantno korist zdravljenja R-FC glede na samo kemoterapijo FC (p = 0,0319, test log rank) (preglednica 8a).
The analysis of the 13C/12C-ratio in carbon dioxide of breath is an integrated part of the diagnostic test Helicobacter Test INFAI.
Analiza razmerja med 13C in 12C v izdihanem ogljikovem dioksidu je sestavni del diagnostičnega postopka z zdravilom Test Helicobacter INFAI za otroke v starosti 3 – 11 let.
The analysis of the 13C/12C-ratio in carbon dioxide of breath is an integrated part of the diagnostic test Helicobacter Test INFAI.
Analiza razmerja med 13C in 12C v izdihanem ogljikovem dioksidu je sestavni del diagnostičnega postopka z zdravilom Test Helicobacter INFAI.
The analysis of the pooled results of the phase III trials corroborated the data obtained in the individual studies regarding reduction of total VTE, major VTE and symptomatic VTE with rivaroxaban 10 mg once daily compared to enoxaparin 40 mg once daily.
Skupna analiza izsledkov iz vseh preskušanj III. faze je potrdila podatke posameznih preskušanj o zmanjšanju pogostnosti vseh VTE, težjih oblik VTE in simptomatskih VTE z rivaroksabanom 10 mg enkrat na dan v primerjavi z enoksaparinom 40 mg enkrat na dan.
The analysis on the global population included (64 patients) showed that the majority had remained at least stable (i.e., without deterioration) based on non-paediatric-specific WHO functional class assessment (97% twice daily, 100% three times daily) and physicians’ global clinical impression (94% twice daily, 93% three times daily) during the treatment period.
Analiza celotne vključene populacije (64 bolnikov) je pokazala, da jih je v času zdravljenja večina ostala vsaj stabilnih (to je, brez poslabšanja) na podlagi ocenjene razvrstive v funkcijske razrede po pediatrično nespecifični klasifikaciji SZO (97 % ob zdravljenju dvakrat dnevno, 100 % trikrat dnevno) ter na podlagi splošne klinične ocene zdravnika (94 % dvakrat dnevno, 93 % trikrat dnevno).
The analysis on the global population included (64 patients) showed that the majority had remained at least stable (i.e., without deterioration) based on non-paediatric-specific WHO functional class assessment (97% twice daily, 100% three times daily) and physicians’ global clinical impression (94% twice daily, 93% three times daily) during the treatment period.
Analiza celotne vključene populacije (64 bolnikov) je pokazala, da jih je v času zdravljenja večina ostala vsaj stabilnih (to je, brez poslabšanja) na podlagi ocenjene razvrstive v funkcijske razrede po pediatrično nespecifični klasifikaciji SZO (97 % ob zdravljenju dvakrat dnevno, 100 % trikrat dnevno) ter na podlagi splošne klinične ocene zdravnika (94% dvakrat dnevno, 93% trikrat dnevno).
The analysis was performed using a Cox proportional hazards model with factors for treatment, time to disease progression on prior penultimate platinum therapy, objective response to prior last platinum therapy and Jewish descent. b Approximately a quarter of placebo treated patients in the BRCA-mutated subgroup (14/62; 22.6%) received a subsequent PARP inhibitor.
Analiza je bila narejena s Coxovim modelom sorazmernih ogroženosti s faktorji za zdravljenje, čas do napredovanja bolezni med predhodnim predzadnjim zdravljenjem na osnovi platine, objektivni odziv na predhodno zadnje zdravljenje na osnovi platine in judovsko poreklo. b Približno četrtina tistih bolnic v podskupini z mutacijo gena BRCA, ki so prejemale placebo (14/62, 22,6 %) je nato dobilo zaviralec PARP.
The analysis was stratified by use of enzyme-inducing antiepileptic drugs (EIAEDs) at randomisation (yes/no).
Analiza je bila stratificirana glede na uporabo antiepileptičnih zdravil, ki inducirajo encime (EIAEDs), ob randomizaciji (da/ne).
The angle between the syringe and skin should not be too narrow (at least 45°, see picture 9).
Kot med brizgo in kožo naj ne bo preoster (vsaj 45°, glejte sliko 9).
The animal will be immune for 40 weeks after the vaccination.
Dokazano je bilo, da je imunost za zmanjševanje lezij zračnih mešičkov trajala do 40 tednov po cepljenju.
The animals received the tablets once or twice a day.
Živali so tablete prejele enkrat ali dvakrat dnevno.
The animals return to normal 1 to 2 days after the peak temperature is observed.
Temperatura se normalizira v 1 do 2 dneh.
The animals return to normal from 1 to 2 days after the peak temperature is observed.
Temperatura se normalizira v 1 do 2 dneh.
The annual rate of lung density decline, as measured by CT scan at total lung capacity (TLC) over 2 years was lower with Respreeza (-1.45 g/L) as compared with placebo (-2.19 g/L), reflecting a 34% reduction (p = 0.017, 1-sided).
Letna stopnja upada pljučne gostote, izmerjene na sliki CT, pri skupni pljučni kapaciteti (TLC, total lung capacity) v 2-letnem obdobju je bila nižja pri zdravilu Respreeza (-1,45 g/l) v primerjavi s placebom (-2,19 g/l), kar kaže na 34- odstotno zmanjšanje (p = 0,017; 1-stransko).
The anterolateral thigh is the preferred site for injection in neonates and infants.
Pri novorojenčkih in dojenčkih je najprimernejše mesto za injiciranje anterolateralni del stegna.
The anti-fracture effect was consistent over the duration of the study.
Učinek proti zlomom je trajal med celotno študijo.
The anti-HA and neutralising antibody responses to A/Indonesia/05/2005 elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from this same strain have been shown to be comparable with the immune responses to A/Vietnam/1194/2004 elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from this same strain.
Odziv anti-HA in odziv nevtralizirajočih protiteles proti A/Indonesia/05/2005, ki ju povzroči cepivo z adjuvansom AS03 in vsebnostjo 3,75 µg HA pridobljeno iz istega seva, sta primerljiva imunskemu odzivu na A/Vietnam/1194/2004, ki ga povzroči cepivo z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljeno iz istega seva.
The anti-HA antibody responses were as follows:
Odzivi protiteles na anti- HA so bili naslednji:
The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
Protitumorsko delovanje topotekana vključuje zavrtje topoizomeraze I. Ta encim je tesno povezan s podvajanjem DNA in odpravlja torzijsko napetost, ki se pojavlja pred napredujočimi replikacijskimi vilicami.
the antibiotic ciprofloxacin used against infections
antibiotik ciprofloksacin, ki se uporablja proti infekcijam
The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with Duloxetine Lilly (see section 4.4).
Antibiotik linezolid je reverzibilen, neselektiven MAOI in ga bolniki, zdravljeni z zdravilom Duloxetine Lilly, ne smejo prejemati (glejte poglavje 4.4).
The antibodies elicited by Nimenrix were similar or higher than those induced by licensed meningococcal vaccines (i.e., MenC-CRM vaccine in subjects aged 12-23 months and ACWY-PS vaccine in subjects older than 2 years of age).
Po cepljenju s cepivom Nimenrix je bila koncentracija protiteles podobna ali večja kot po odobrenih meningokoknih cepivih (tj. cepivu MenC-CRM pri preskušancih, starih od 12 do 23 mesecev, in cepivu ACWY-PS pri preskušancih, starejših od 2 let).
The antibodies had no inhibitory activity, and the subject did not experience any adverse events or bleeding in association with these antibodies.
Ta protitelesa pri bolniku niso delovala zaviralno in preiskovanec v zvezi s temi protitelesi ni imel neželenih učinkov ali krvavitev.
The antibodies will help to protect against the diseases caused by these viruses.
Protitelesa mu bodo pomagala pri zaščiti pred boleznim, ki jih povzročajo ti virusi.
The antibodies will help to protect against the diseases caused by these viruses.
Protitelesa mu bodo pripomogla pri zaščiti pred boleznimi, ki jih povzročajo ti virusi.
The antibodies will help to protect against the diseases caused by these viruses.
Ta bodo pomagala pri zaščiti pred boleznimi, ki jih povzročajo ti virusi.
The antibody persistence rates 1 year postvaccination in recipients of a single dose of ProQuad were 98.9% (1722/1741) for measles, 96.7% (1676/1733) for mumps, 99.6% (1796/1804) for rubella, and 97.5% (1512/1550) for varicella (≥5 gpELISA Units/ml).
1 leto po cepljenju so se protitelesa (≥ 5 gpELISA enot/ml) proti ošpicam ohranila pri 98,9 % (1.722/1.741) prejemnikov enega odmerka cepiva ProQuad, protitelesa proti mumpsu pri 96,7 % (1.676/1.733), proti rdečkam pri 99,6 % (1.796/1.804) in protitelesa proti noricam pri 97,5 % (1.512/1.550) prejemnikov.
The antibody response to HPV-16 and HPV-18 was measured using a type-specific direct ELISA (version 2, MedImmune methodology, modified by GSK) which was shown to correlate with the pseudovirion-based neutralisation assay (PBNA).
Protitelesni odziv proti HPV-16 in HPV-18 je bil ovrednoten z uporabo genotipsko specifičnih direktnih ELISA testov (različica 2, metodologija MedImmune, spremenjena s strani GSK), za katere je bila dokazana soodvisnost s testom nevtralizacije psevdoviriona (PBNA – pseudovirion-based neutralisation assay).
The antibody response to HPV-16 and HPV-18 was measured using a type-specific direct ELISA (version 2, MedImmune methodology, modified by GSK) which was shown to correlate with the pseudovirion-based neutralisation assay (PBNA).
Protitelesni odziv proti HPV-16 in HPV-18 je bil ovrednoten z uporabo genotipsko specifičnih direktnih ELISA testov (različica 2. metodologija MedImmun, spremenjena s strani GSK), za katere je bila dokazana soodvisnost s testom nevtralizacije psevdoviriona (PBNA – pseudovirion-based neutralisation assay).
The antibody response to other vaccines may be diminished (see also 4.4).
Tudi odziv protiteles na druga cepiva je lahko zmanjšan (glejte tudi poglavje 4.4).
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics, and dipyridamole.
Antiholinergična aktivnost oksibutinina se poveča s sočasno uporabo drugih antiholinergikov ali zdravil z antiholinergičnim delovanjem, kot so amantadin in druga antiholinergična zdravila proti Parkinsonovi bolezni (npr. biperiden, levodopa), antihistaminiki, antipsihotiki (npr. fenotiazini, butirofenoni, klozapin), kinidin, triciklični antidepresivi, atropin in sorodne spojine, kot so atropinski spazmolitiki in dipiridamol.
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics, dipyridamole.
Antikolinergično delovanje oksibutinina je povečano ob sočasnem jemanju drugih antikolinergikov ali zdravil z antikolinergičnim delovanjem, kot so na primer amantadin ali druga antikolinergična antiparkinsonska zdravila (npr. biperiden, levodopa), antihistaminiki, antipsihotiki (npr. fenotiazini, butirofenoni, klozapin), kvinidin, triciklični antidepresivi, atropin in sorodne učinkovine, kot so atropinski spazmolitiki, dipiridamol.
The anticoagulant effect of desirudin is poorly reversible. aPTT levels can, however, be reduced by intravenous administration of DDAVP (desmopressin).
Antikoagulantni učinek desirudina je slabo reverzibilen. aPTČ je mogoče skrajšati z intravensko uporabo DDAVP (dezmopresina).
The anticoagulant effects can be largely neutralised by the slow intravenous injection of protamine sulphate or protamine hydrochloride.
Antikoagulantni učinek je mogoče v veliki meri nevtralizirati s počasnim intravenskim injiciranjem protaminijevega sulfata ali protaminijevega hidroklorida.
The anticoagulant effects can be largely neutralised by the slow intravenous injection of protamine sulphate or protamine hydrochloride.
Antikoagulantni učinek je mogoče v veliki meri nevtralizirati s počasnim intravenskim injiciranjem protaminijevega sulfata ali protaminijevega klorida.
the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
antikonvulzivi: karbamazepin, okskarbazepin, fenobarbital, fenitoin,
the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
antikonvulzanti karbamazepin, okskarbazepin, fenobarbital, fenitoin;
The antiemetic activity of EMEND was evaluated over a 5-day (120 hour) period following the initiation of chemotherapy on Day 1.
Antiemetično delovanje zdravila EMEND so ocenili v 5-dnevnem (120-urnem) obdobju po uvedbi kemoterapije 1. dan.
The antiemetic activity was observed during 0-24 hours, 24-120 hours and 0-120 hours.
Antiemetično aktivnost so opazovali v obdobju 0-24 ur, 24- 120 ur in 0-120 ur.
The antiemetic agent, domperidone, has the potential to increase QT interval prolongation and to induce “torsade de pointes”- arrhythmias; therefore, co-administration with domperidone should be avoided.
Antiemetik domperidon lahko podaljša interval QT in povzroči aritmijo “torsade de pointes”, zato se je treba sočasni uporabi z domperidonom izogibati.
The antiepileptic drug hypersensitivity syndrome occurred in close temporal association to the initiation of rufinamide therapy and in the paediatric population.
Ta preobčutljivostni sindrom, povezan z uporabo antiepileptičnega zdravila, se je pojavljal v tesni časovni zvezi z uvedbo zdravljenja z rufinamidom in pri pediatrični populaciji.
The antigen should be stored for no longer than 12 months at 2-8ºC pending the provision of data supporting a longer period of storage.
Antigena se ne sme shranjevati dlje kot 12 mesecev pri temperaturi 2–8 ºC, dokler ne bo na voljo nadaljnjih podatkov, na podlagi katerih bo možno daljše obdobje shranjevanja.
The antigens are adjuvanted with 150 mg dl--tocopherol acetate per dose.
En odmerek antigenov vsebuje 150 mg dl--tokoferol acetate kot adjuvans.
The antihypertensive effect is largely manifested within 1 week and the maximum effect is generally seen within 4 weeks.
Antihipertenzivno delovanje se večinoma pokaže v prvem tednu, največji učinek pa doseže v 4 tednih.
The antihypertensive effect persists constantly over 24 hours after dosing and includes the last 4 hours before the next dose as shown by ambulatory blood pressure measurements.
Antihipertenzivni učinek ostaja enakomeren 24°ur po zaužitju zdravila, tudi zadnje 4°ure pred naslednjim odmerkom, kar so pokazala ambulantna merjenja krvnega tlaka.
The antihypertensive efficacy of telmisartan is comparable to that of agents representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril).
Antihipertenzivna učinkovitost telmisartana je primerljiva z učinkovitostjo zdravil iz drugih skupin antihipertenzivnih zdravil (primerljivost dokazujejo klinična preskušanja, v katerih so telmisartan primerjali z amlodipinom, atenololom, enalaprilom, hidroklorotiazidom in lizinoprilom)
The antimicrobial activity of Convenia following a single injection lasts for up to 14 days.
Protimikrobno delovanje zdravila Convenia po enkratnem dajanju traja do 14 dni.
The antimicrobial effectiveness of valnemulin against bacteria causing the claimed diseases in pigs was studied in microbiological laboratories.
Protimikrobno učinkovitost valnemulina v primeru bakterij, ki pri prašičih povzročajo navedene bolezni, so proučevali v mikrobioloških laboratorijih.
the antimycobacterials rifampicin, rifapentine
protimikobakterijskimi zdravili: rifampicin, rifapentin,
the antimycobacterials rifampicin, rifapentine;
zdravila za zdravljenje okužb z mikobakterijami rifampicin, rifapentin;
The antithrombotic activity is mediated by antithrombin III (ATIII), resulting in human antithrombotic effect.
Te antitrombotične učinke posreduje antitrombin III (ATIII); posledica je antitrombotično delovanje pri človeku.
The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.
Kombinacija z zaviralci nukleozidne reverzne transkriptaze (NRTI) didanozinom, emitricitabinom, lamivudinom, stavudinom, tenofovirjem, zalcitabinom ali zidovudinom, zaviralcem ne-nukleozidne reverzne transkriptaze (NNRTI) nevirapinom ali zaviralcem proteaze (PI) amprenavirjem ni imela antagonističnega učinka na protivirusno aktivnost abakavirja.
The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, stavudine, tenofovir or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.
Protivirusno delovanje abakavirja v celični kulturi ni bilo antagonistično v kombinaciji z nukleozidnimi zaviralci reverzne transkriptaze (NRTI) didanozinom, emtricitabinom, stavudinom, tenofovirjem ali zidovudinom, nenukleozidnim zaviralcem reverzne transkriptaze (NNRTI) nevirapinom ali zaviralcem proteaz (PI) amprenavirjem.
The antiviral activity of elvitegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cells, monocyte/macrophage cells, and peripheral blood lymphocytes and the 50% effective concentration (EC50) values were in the range of 0.02 to 1.7 nM.
Protivirusna aktivnost elvitegravirja proti laboratorijskim in kliničnim izolatom HIV-1 je bila ocenjena v limfoblastoidnih celicah, monocitih/makrofagih in limfocitih v periferni krvi, pri čemer so bile vrednosti 50-odstotno učinkovite koncentracije (EC50) v razponu od 0,02 do 1,7 nM.
The antiviral activity of elvitegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cells, monocyte/macrophage cells, and peripheral blood lymphocytes and the 50% effective concentration (EC50) values were in the range of 0.02 to 1.7 nM.
Protivirusna aktivnost elvitegravirja v primerjavi z laboratorijskimi in kliničnimi izolati HIV-1 je bila ocenjena v limfoblastoidnih celicah, monocitnih/makrofagnih celicah in limfocitih v periferni krvi, pri čemer so bile vrednosti 50-odstotno učinkovite koncentracije (EC50) v razponu od 0,02 do 1,7 nM.
The antiviral activity of tenofovir disoproxil fumarate against hepatitis B virus (HBV) has been demonstrated in vitro and clinically in adults and adolescents.
Protivirusna aktivnost dizoproksiltenofovirijevega fumarata proti virusu hepatitisa B (HBV) je bila dokazana in vitro in klinično pri odraslih in mladostnikih.
The antiviral response to tenofovir disoproxil fumarate was durable through 48 weeks (DAVG48 was -0.57 log10 copies/ml, proportion of patients with HIV-1 RNA below 400 or 50 copies/ml was 41% and 18% respectively).
Protivirusni učinek dizoproksiltenofovirijevega fumarata je bil izražen skozi 48 tednov (DAVG48 je bila -0,57 log10 kopij/ml, delež pacientov z HIV-1 RNA pod 400 kopij/ml je bil 41%, s pod 50 kopij/ml pa 18%).
The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dL and 2.0 mg/dL).
V študiji APEX je bila ocenjena učinkovitost pri 40 bolnikih z okvaro delovanja ledvic (tj. izhodiščna vrednost kreatinina v serumu > 1,5 mg/dl in ≤ 2,0 mg/dl).
The Apidra cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Apidra se uporabljajo samo z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar ali JuniorSTAR (glejte poglavje 4.4).
The Apidra cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Apidra so namenjeni samo za uporabo z injekcijskimi peresniki OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
The Apidra cartridges should only be used with the following pens:
Vložki zdravila Apidra se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of VTE in a broad range of adult patients undergoing elective hip or knee replacement.
Klinični program apiksabana je bil zasnovan za dokaz učinkovitosti in varnosti uporabe apiksabana pri preprečevanju venskih trombemboličnih dogodkov pri širokem spektru odraslih bolnikov po kirurški zamenjavi kolka ali kolena.
The apparent clearance at steady state is 26 l/h.
Navidezni očistek zdravila v stanju dinamičnega ravnovesja je 26 l/h.
The apparent clearance of ara-G (Cl/F) is comparable between the two groups [9.5 l/h/m2 (35 %) in adult patients and 10.8 l/h/m2 (36 %) in paediatric patients] on day 1.
Na 1. dan je navidezni očistek ara-G (Cl/F) primerljiv med obema starostnima skupinama (9,5 l/h/m2 (35 %) pri odraslih bolnikih in 10,8 l/h/m2 (36 %) pri otrocih).
The apparent distribution volume of telavancin at steady-state in healthy adult subjects was approximately 133 ml/kg.
Navidezen volumen porazdelitve telavancina v stanju dinamičnega ravnovesja pri zdravih odraslih osebah je približno 133 ml/kg.
The apparent effects were greater during chronic than acute administration.
Zabeleženi učinki so bili pri kroničnem dajanju obsežnejši kot pa pri akutni izpostavitvi.